5-ASA therapy and renal function in inflammatory bowel disease [5]

American Journal of Gastroenterology

Volumn 100, Issue 2, 2005, Pages 501-

  Siveke, Jens T ^a   Egert, Julia ^a   Sitter, Thomas ^a   Schiemann, Uwe ^a   Walcher, Petra ^a   Török, Helga Paula ^a   Glas, Jürgen ^a   Folwaczny, Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIC NEPHROPATHY; CREATININE CLEARANCE; ENTERITIS; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; LETTER; MAINTENANCE THERAPY; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; NOTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; MESALAMINE; NEPHRITIS, INTERSTITIAL;

EID: 19744383971     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.t01-5-41219.x     Document Type: Letter

References (3)

1. Dehmer C, Greinwald R, Loffler J, et al: German Salofalk Study Group. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: A prospective study in patients with inflammatory bowel diseases. Int J Colorectal Dis 2003;18:406-12.
2. Izzedine H, Simon J, Piette AM, et al. Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 2002;123:1436-40.
3. Van Staa TP, Travis S, Leufkens HGM, et al. 5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study. Gastroenterology 2004;126:1733-9.